JOURNAL of
ONCOLOGICAL
SCIENCES

ORIGINAL RESEARCH ARTICLE

The Comparison of Central Venous Port Catheters in Gastrointestinal Cancer Treatment
Received Date : 13 Jul 2019
Accepted Date : 16 Dec 2019
Available Online : 10 Feb 2020
Doi: 10.37047/jos.2019-73122 - Article's Language: EN
J Oncol Sci. 2020;6(1):10-4
This is an open access article under the CC BY-NC-ND license
ABSTRACT
Objective: Patients with solid cancers frequently suffer from thrombosis, which is associated with considerable cost, morbidity, and mortality. The infusional chemotherapy regimen, especially in gastrointestinal cancers, has a long-term need for central venous catheterization. Implantable ports (IP) are increasingly used for the administration of chemotherapy and supportive treatment to cancer patients. Material and Methods: In this study, we evaluated the factors affecting the port thrombosis in gastrointestinal cancers. The patients with gastric, colorectal and pancreatic cancer were included in the study. Results: There were 113 patients with IP locations on subclavian and 7 on femoral veins. IP thromboses were detected in 10 patients. One of the patients had two thrombosis sites on both femoral and subclavian veins. The median time duration from the placement of the port to thrombosis was 4 months. There were 9 patients who underwent treatment with low molecular weight heparin, while one patient received warfarin treatment. There were ten non-port events related to thrombosis events. There was a significant difference between port thrombosis due to location (p<0.0001). This study showed increased thrombotic events in femoral IPs. Pulmonary embolization due to port thrombosis was not observed. Time to thrombose was significantly shorter in femoral IPs (p=0.04). Conclusion: Although femoral IPs have been reported to be safe for the use of breast cancers, great attention must be paid for the utilization of femoral IPs in gastrointestinal cancers. Prospective and larger trials are needed to confirm the results of the present study.
KAYNAKLAR
  1. Mandalà M, Falanga A, Roila F. Management of venous thromboembolism (VTE) in cancer patients: ESMO clinical practice guidelines. Ann Oncol. 2011;22(suppl 6):85-92. [Crossref]  [PubMed] 
  2. Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 suppl):e195S-e226S. [Crossref] 
  3. Lyman GH, Bohlke K, Khorana AA, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014. J Clin Oncol. 2015;33(6):654-656.
  4. Farge D, Debourdeau P, Beckers M, et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost. 2013;11(1):56-70.
  5. Streiff MB, Holmstrom B, Ashrani A, et al. Cancer-associated venous thromboembolic disease, version 1.2015. J Natl Compr Cancer Netw. 2015;13(9):1079-1095. [Crossref]  [PubMed] 
  6. Zwicker JI, Connolly G, Carrier M, Kamphuisen PW, Lee AY. Catheter-associated deep vein thrombosis of the upper extremity in cancer patients: Guidance from the SSC of the ISTH. J Thromb Haemost. 2014;12(5): 796-800. [Crossref]  [PubMed] 
  7. Seiler CM, Frohlich BE, Dorsam UJ, Kienle P, Buchler MW, Knaebel HP. Surgical technique for totally implantable access ports (TIAP) needs improvement: a multivariate analysis of 400 patients. J Surg Oncol. 2006;93(1):24-29. [Crossref]  [PubMed] 
  8. Bertoglio S, DiSomma C, Meszaros P, Gipponi M, Cafiero F, Percivale P. Long-term femoral vein central venous access in cancer patients. Eur J Surg Oncol. 1996;22(2):162-165. [Crossref] 
  9. Schiffer CA, Mangu PB, Wade JC, et al. Central venous catheter care for the patient with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2013;31(10):1357-1370. [Crossref]  [PubMed] 
  10. Kucher N. Deep-vein thrombosis of the upper extremities. N Engl J Med. March 2011;(364): 861-869. [Crossref]  [PubMed] 
  11. Debourdeau P, Chahmi DK, Zammit C, Farge-Bancel D. Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. Pathol Biol (Paris). 2008;56(4):211-219 [Crossref]  [PubMed] 
  12. Boussen H, Mtaallah M, Dhiab T, et al. Evaluation of implantable sites in medical oncology in Tunisia. Prospective study of 205 cases. Ann Fr Anesth Reanim. 2001;20(6): 509-513. [Crossref] 
  13. Teichgräber U, Nagel SN, Kausche S. Evaluation of correlations between underlying disease and port complications. Rofo. 2014; 186(5):496-500. [Crossref]  [PubMed] 
  14. Gouin-Thibault I, Achkar A, Samama MM. The thrombophilic state in cancer patients. Acta Haematol. 2001;106(1):33-42. [Crossref]  [PubMed] 
  15. Debourdeau P, Farge D, Beckers M, et al. International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer. J Thromb Haemost. 2013;11(7):71-80. [Crossref]  [PubMed] 
  16. Horsted F, West J, Grainge MJ. Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLoS Med. 2012;9(7):e1001275. [Crossref]  [PubMed]  [PMC] 
  17. Agnelli G, Gussoni G, Bianchini C, et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol. 2009;10(10):943-949. [Crossref] 
  18. Agnelli G, George DJ, Kakkar AK, et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med. 2012;366(7):601-609. [Crossref]  [PubMed] 
  19. Hohl Moinat C, Periard D, Grueber A, et al. Predictors of venous thromboembolic events associated with central venous port insertion in cancer patients. J Oncol. 2014;2014: 743181. [Crossref]  [PubMed]  [PMC] 
  20. Chen SY, Lin CH, Chang HM, Hsu HM, Yu JC. A safe and effective method to implant a totally implantable access port in patients with synchronous bilateral mastectomies: modified femoral vein approach. J Surg Oncol. 2008;98(3):197-199. [Crossref]  [PubMed] 
  21. Decousus H, Bourmaud A, Fournel P, et al. Cancer-associated thrombosis in patients with implanted ports: a prospective multicenter French cohort study (ONCOCIP). Blood. 2018;132(7):707-716. [Crossref]  [PubMed] 
  22. Akl EA, Ramly EP, Kahale LA, et al. Anticoagulation for people with cancer and central venous catheters. Cochrane Database Syst Rev. 2014;15(10):CD006468. [Crossref] 
  23. D'Ambrosio L, Aglietta M, Grignani G. Anticoagulation for central venous catheters in patients with cancer. N Engl J Med. 2014;37(14):1362-1363. [Crossref]  [PubMed]